Gastroparesis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Gastroparesis}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{Reflis..." |
Aditya Ganti (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Gastroparesis}} | {{Gastroparesis}} | ||
{{CMG}} ; {{AE}} {{ADG}} | |||
==Overview== | |||
==Future or investigational therapies== | |||
*In patients with diabetic gastroparesis, ghrelin and motilin receptors, are the two key pharmacological targets, that have emerged for novel therapeutic options. | |||
*The intravenously administered cyclic ghrelin analog, TZP-101, was demonstrated to accelerate gastric emptying and improve symptom severity when compared with placebo. | |||
*When studied in a phase IIa clinical trial, the oral counterpart, TZP-102, showed promise in that significant improvement in symptoms were seen (although there was no change in gastric emptying) after 4 weeks of treatment | |||
*The follow-up 12-week phase IIb trial 76 failed to demonstrate a benefit; however, and it seems further investigation of this agent is not being pursued. | |||
*Relamorelin (RM-131) is a synthetic small molecule ghrelin agonist which, when administered as a one-time subcutaneous injection, has been demonstrated to accelerate gastric emptying in patients with diabetic GP. | |||
*In a 4-week, phase II clinical trial, twice daily relamorelin improved gastric emptying as measured by breath testing and improved subjective vomiting severity as compared with placebo. | |||
*Other GP symptom measurements were not significantly improved, however, Camicinal (GSK962040) is a small molecule selective motilin receptor agonist that was developed based on the mechanism and molecular structure of macrolide antibiotics. | |||
*Camicinal improves gastric empting in diabetic GP as demonstrated in several phase I clinical trials 80 and preliminary results of a phase II clinical trial demonstrates significant symptom improvement above placebo. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 16:28, 7 February 2018
|
Gastroparesis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Gastroparesis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Gastroparesis future or investigational therapies |
|
Gastroparesis future or investigational therapies in the news |
|
Risk calculators and risk factors for Gastroparesis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Future or investigational therapies
- In patients with diabetic gastroparesis, ghrelin and motilin receptors, are the two key pharmacological targets, that have emerged for novel therapeutic options.
- The intravenously administered cyclic ghrelin analog, TZP-101, was demonstrated to accelerate gastric emptying and improve symptom severity when compared with placebo.
- When studied in a phase IIa clinical trial, the oral counterpart, TZP-102, showed promise in that significant improvement in symptoms were seen (although there was no change in gastric emptying) after 4 weeks of treatment
- The follow-up 12-week phase IIb trial 76 failed to demonstrate a benefit; however, and it seems further investigation of this agent is not being pursued.
- Relamorelin (RM-131) is a synthetic small molecule ghrelin agonist which, when administered as a one-time subcutaneous injection, has been demonstrated to accelerate gastric emptying in patients with diabetic GP.
- In a 4-week, phase II clinical trial, twice daily relamorelin improved gastric emptying as measured by breath testing and improved subjective vomiting severity as compared with placebo.
- Other GP symptom measurements were not significantly improved, however, Camicinal (GSK962040) is a small molecule selective motilin receptor agonist that was developed based on the mechanism and molecular structure of macrolide antibiotics.
- Camicinal improves gastric empting in diabetic GP as demonstrated in several phase I clinical trials 80 and preliminary results of a phase II clinical trial demonstrates significant symptom improvement above placebo.